Moroccan pharmaceutical group Laprophan has completed its first European acquisition, taking a majority stake in Swiss company Rivopharm. Rivopharm specializes in high-value specialty medicines and pharmaceutical solutions. The deal, finalized on June 17th, marks a significant milestone for the Moroccan pharmaceutical industry, according to Laprophan’s Dr. Farid Bennis. He described the acquisition as historic, signifying international recognition for Moroccan pharmaceutical capabilities, particularly within Switzerland’s established pharmaceutical sector. The acquisition expands Laprophan’s reach into the European market and strengthens its position in the specialty pharmaceutical space. Further details of the financial terms were not immediately disclosed. This move signals a growing trend of North African pharmaceutical companies seeking expansion through strategic acquisitions in Europe.